The European Paediatric Formulation Initiative (EuPFI) Conference 2024 on ‘Formulating Better Medicines for Children’ organized in partnership with the International Association for Pharmaceutical Technology (APV) was held on 17 – 19 September 2024 in Rotterdam, The Netherlands.

The conference fostered vibrant discussions on leveraging recent innovations and progress in global paediatric medicine development with more than 125 delegates from 21 countries. Scientists from renowned institutions worldwide delivered inspiring scientific presentations, highlighting critical considerations for paediatric formulation research. The primary aim of EuPFI is to foster collaborative ideas to develop patient-centred drug products specifically designed for children. Bringing together experts from diverse backgrounds, the conference acts as a platform for dynamic knowledge exchange to address children's unique needs and shape the future of paediatric formulations. 33 posters were displayed, offering students and early-career scientists an opportunity to share their research, ideas, and discoveries.

A heartfelt thank you extends to our presenters, sponsors, exhibitors, scientific organizers, session chairs, poster judges, conference secretariat, volunteers, and all those who lent their support to the conference. Also a special thanks is extended to the attendees who brought their specialised knowledge and intellectual rigour to the event. Your enthusiasm and active engagement were truly inspiring and played a crucial role in the event's success. EuPFI is committed to sustaining this momentum with more to come in the future.

As we look forward to #EuPFI2025, stay tuned for updates on the venue and dates, as the journey to advance paediatric formulation research continues

Programme

EuPFI 2024 Programme - Click here

Sign up to our mailing list here and we will send you an email when the programme is online and keep visiting the website for conference updates in the meanwhile

Poster Presentations

Abstacts

List of EuPFI2024 abstracts

Posters

iD2: Net Promoter Score Model for Evaluating Paediatric Medicine Acceptability: Validation and Feasibility Study
Okhee Yoo, University of Western Australia, Australia

ID3: The odour acceptability of oral flucloxacillin formulations assessed using a human sensory panel
Ayat Elgammal, University College Cork, Ireland

ID4: Development of child-appropriate extended-release tablets based on lipid matrix systems
Stefanie Broocks, University of Greifswald, Germany

ID5: Assessment of choking hazard of an age-appropriate patient-centric novel dosage form designed to minimize choking hazards in special patient populations
Srinivasan Shanmugam, Adare Pharma Solutions, United States

ID6: Safety and acceptability of placebo pellets co-administered with a swallowing gel in healthy volunteers
Goedele Craye, Ghent University, Belgium

ID8: Printed drug-loaded temporary tattoos – A novel, highly acceptable pre-treatment option for pain-free vaccinations for children
Manuel Zettl, Research Center Pharmaceutical Engineering GmbH, Austria

ID9: Personalized Medication using 3D Printed Technology: Case studies in a University Hospital
Jayeeta Sengupta, Netherlands Organization for Applied Scientific Research, Netherlands

ID11: Development and verification of standard vehicles for investigating the compatibility of oral paediatric drug products with fruit juices
Carolin Eckert, University of Greifswald, Germany

ID12: Individualised dosing using an innovative minitablet dosage manager
Jafar Shendi, OnDosis AB, Sweden

ID13: Investigating the influence of co-administered milk on the in vitro disintegration of mini-tablets with taste-masking coatings
Frank Karkossa, University of Greifswald, Germany

ID14: Multifunctional excipients for pediatric oral suspensions
Pawel Balcerzak, Lubrizol, Poland

ID15: From Bench to Bedside: Solid-State Extrusion 3D Printing of Sulfamethoxazole & Trimethoprim for Clinical Translation
Maxime Stoops, Institut gustave roussy, France

ID16: Establishing a National Priority List of Pediatric Drugs in Canada – A Case for Close Collaboration with Regulators
Sophie Bérubé, GPFC of the CHU Sainte-Justine, Canada

ID17: Forging New Partnerships to Advance Pediatric Formulations: An Update on NIH Activities Supporting Product Development
Sheryl Zwerski, Division of AIDS/National Institute of Allergy and Infectious Diseases/U.S. National Institutes of Health, United States

ID18: Development and evaluation of omeprazole and esomeprazole magnesium-based delayed-release tablet formulations for paediatric use
Stella Roumpou, National and Kapodistrian University of Athens, Greece

ID19: Achieving individualised dosing with pellet formulations combined with an innovative device technology
Emelie Svensson, OnDosis AB, Sweden

ID20: Pan-India study on user perspectives of minitablets for paediatric treatments
Soniya Notani, University College London School of Pharmacy, United Kingdom

ID21: Parent acceptability of different forms of oral hydrocortisone
Andrea Gill, Alder Hey Children's NHSFT, United Kingdom

ID22: Stability Study of Pediatric Oral Suspensions Indicated in the Treatment of Cardiovascular Disease
Maria Carvalho, Professional Compounding Centers of America (PCCA), United States

ID23: Predictive dissolution testing of a novel taste-masked multiparticulate dosage form of artesunate/amodiaquine for paediatric malaria therapy
Frank Karkossa, University of Greifswald, Germany

ID24: Innovative Formulation Strategies for orodispersible Loratadine Dosage Forms
Almut von der Brelie, Merck Life Science KGaA, Germany

ID25: An Investigation into the Feasibility of a Novel Genericised Paediatric Dispersible Platform
Karis Clifton, GSK, United Kingdom

ID26: Ataxia Telangiectasia: Drug Repositioning for Pediatric Treatment of a Rare Genetic Neurological Disease
Cinzia Cimino, University of Catania, Italy

ID27: Easy Scale-up of Wurster Processes for Pellet Drug Layering and Taste Masking
Annette Grave, Glatt Pharmaceutical Services GmbH und Co. KG, Germany

ID28: The human descriptive sensory panel - a tool for understanding how bitter taste is impacted during formulation
Liz Sheehan, SRL Pharma, Ireland

ID30: Development of loratadine minitablets using 3D printing technology
Anđelka Račić, University of Banja Luka, Bosnia and Herzegovina

ID31: Advancements in Personalized Pediatric Medicine: Optimizing and Implementing 3D-Printed Tablets in Clinical Practice
Jayeeta Sengupta, Netherlands Organization for Applied Scientific Research, Netherlands

ID33: Gel Forming Tablets: Formulations with different gel former combinations and their characterization
Peter Kühl, Pharmaceutical R&D NCEs, Switzerland

ID34: Solubility measurement of BCS class II drugs in fasted state paediatric and adult simulated intestinal fluid
Zoe McKinnon, University of Strathclyde, United Kingdom

ID35: Calcium phosphate microcapsules for paediatric drug delivery
Jonas Kost, Galvita AG, Switzerland

ID36: Exploring the Implications of Poor Patient Acceptability on Adherence and Clinical Outcomes: A Pharmacometrics case Study with Deferasirox
Elisa Alessandrini, University College London School of Pharmacy, United Kingdom

ID37: Children and parent views of 3D printed gummy bears as an alternative dosage form for children – an interim analysis
Louise Bracken, Alder Hey Children's NHS Foundation Trust, United Kingdom

ID38: Design of taste-masked primaquine – ion exchange resin complex intended for pediatric formulations
Thiago Guimarães, Fundação Oswaldo Cruz, Brazil

ID39: Assessment of in vivo antimalarial activity of primaquine-ion exchange resin complex against Plasmodium berghei ANKA
Thiago Guimarães, Fundação Oswaldo Cruz, Brazil

ID40: Accelerating Safer Administration of Medicines to Children in Low Resource Settings
Sifan Hu, University College London School of Pharmacy, United Kingdom

Soapbox Session Presentations

Development of child-appropriate extended-release tablets based on lipid matrix systems
Stefanie Broocks, University of Greifswald, Germany

Establishing a National Priority List of Paediatric Drugs in Canada – A Case for Close Collaboration with Regulators
Raphael Kraus, Goodman Pediatric Formulations Centre (GPFC), Canada

Pan-India study on user perspectives of minitablets for paediatric treatments
Soniya Notani, and Elisa Alessandrini, University College London School of Pharmacy, United Kingdom

Printed drug-loaded temporary tattoos – A novel, highly acceptable pre-treatment option for pain-free vaccinations for children
Manuel Zettl, Research Center Pharmaceutical Engineering GmbH, Austria

Development and verification of standard vehicles for investigating the compatibility of oral paediatric drug products with fruit juices
Carolin Eckert, University of Greifswald, Germany

Short Talks Presentations

Hospital compounding as exploratory formulation approach: bridging unmet paediatric user needs and early industrial development. Chemotherapy case studies
Maxime Annereau, Gustave Roussy Cancer Center, Institut des Sciences Moléculaires d‘Orsay (ISMO), France

Assessment of choking hazard of an age-appropriate patient-centric novel dosage form designed to minimize choking hazards in special patient populations
Srinivasan Shanmugam, Adare Pharma Solutions, United States

Individualised dosing using an innovative minitablet dosage manager
Jafar Shendi, OnDosis AB, Sweden

The role of phospholipids in infant nutrition and their use as safe and effective excipients for pediatric formulations
Richard Wibel, Lipoid GmbH, Germany

High performance pediatric oral suspensions
Pawel Balcerzak, Lubrizol, Poland

Session Presentations

Success Stories and Case Studies of Approved Products

Development and approval of an oro-dispersible mini tablet for treatment of children from birth
Emily Sheppard, Proveca, United Kingdom

Finlee® dispersible tablets: simple dosage form for flexible dosing
Sarah David, Novartis, Switzerland

Insights into the results of the CAMEO study - children‘s acceptability of minitablets mixed with food
Louise Bracken, Alder Hey Children‘s Hospital, United Kingdom

Excipients Hazards • Risks • Impact – How can we overcome it?

Global Regulatory Picture
Kevin Hughes, Colorcon, IPEC, United Kingdom

Alternatives from a technical perspective
Mike Tobyn, Bristol-Myers Squibb, United Kingdom

International chapter on paediatric formulation development

Forging new partnerships to advance paediatric formulations: an update on nih activities supporting product development
Sheryl Zwerski, Division of AIDS/National Institute of Allergy and Infectious Diseases/U.S. National Institutes of Health, USA

The GAP-f Paediatric Technology Hub
Martina Penazzato, World Health Organization, Switzerland
Sébastien Morin, Medicines Patent Pool, Switzerland

Involving families with preterm babies in PPI - conect4children- Stichting
Mark Turner, conect4children, United Kingdom
Segolene Gaillard, Hospices Civils de Lyon - HCL, France

Plenary Session

Pediatric enteroids to study oral drug absorption: hype or reality?
Saskia N. de Wildt, Intensive Care and Department of Pediatric Surgery, Erasmus MC-Sophia Children’s Hospital, The Netherlands

Parenteral medicines for neonates and infants

Acceptability talk
Fiona O‘Brien, RCSI, Ireland

User centric development of pediatric protein-based therapeutics: case studies and perspectives from the IQ Pediatric Consortium (virtual talk)
Annette Medina, AstraZeneca, USA

Clinical challenges associated with parenteral delivery to neonates
Karel Allegaert, KU Leuven, Belgium/ Erasmus MC, Rotterdam

Preconference Workshop Presentations

Challenges and Opportunities to Develop Oral Pediatric Medicines for Neonates and Infants
17th September 2024
Rotterdam, The Netherlands

Focus Session Presentations

Blocking the bitter taste of medicines: From real world to benchside to bedside
David Clapham, Consultant, UK
Sejal Ranmal, UCL School of Pharmacy, UK
Peihua Jiang, Monell Chemical Senses Center, USA
Rose Elliott, Routes2Results, UK

Panel discussion: Small pellets for small kids: Big teamwork
Fang Liu, Fluid Pharma Ltd, UK
Daniel Schaufelberger, NGT Biopharma Consultants, United States
Annette Grave, Glatt Pharmaceutical Services GmbH, Germany
Catherine Tuleu, Sejal Ranmal, UCL School of Pharmacy, United Kingdom
Sandra Klein, University of Greifswald, Germany

Roundtable discussion and Q&A on drug-device interface: Minitablet administration case study
Jenny Walsh, Jenny Walsh Consulting Ltd., UK
Gary Inwards, MHRA, UK
Esmeralda Hermans, Johnson&Johnson Innovative Medicine, Belgium
Leonie Wagner, Roche, Switzerland

PCCA Award Winners

The Professional Compounding Centers of America (PCCA) sponsored three poster awards and one oral presentation award.

Winners of the poster awards:
Ayat Elgammal, University College Cork, Ireland
Odour acceptability of oral flucloxacillin formulations: A sensory study

Stefanie Brooks, University of Greifswald, Germany
Development of child-appropriate extended-release tablets based on lipid matrix systems

Sifan Hu, University College London, UK
Accelerating Safer Administration of Medicines to Children in Low Resource Settings

Winner of the oral presentation award:
Elisa Alessandrini, University College London, UK
Pan-India study on user perspectives of minitablets for paediatric treatments

Picture Gallery

Contacts

16^th Conference of the European Paediatric Formulation Initiative

Conference Secretariat

APV
International Association for Pharmaceutical Technology
Kurfürstenstraße 59, 55118 Mainz/Germany

Tel.: +49 6131 9769-0
Fax: +49 6131 9769-69
Website: www.apv-mainz.de
E-mail: apv@apv-mainz.de

European Paediatric Formulation Initiative

Website: www.eupfi.co.uk
E-mail: admin@eupfi.co.uk

University College London School of Pharmacy, 29-39, Brunswick Square London , WC1N 1AX Phone:+44 20 3987 2885 Fax: 0044 20 7753 5942 ;